CL2008002092A1 - Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. - Google Patents

Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.

Info

Publication number
CL2008002092A1
CL2008002092A1 CL2008002092A CL2008002092A CL2008002092A1 CL 2008002092 A1 CL2008002092 A1 CL 2008002092A1 CL 2008002092 A CL2008002092 A CL 2008002092A CL 2008002092 A CL2008002092 A CL 2008002092A CL 2008002092 A1 CL2008002092 A1 CL 2008002092A1
Authority
CL
Chile
Prior art keywords
antifusogenic
conjugate
antibody
production
pharmaceutical composition
Prior art date
Application number
CL2008002092A
Other languages
English (en)
Inventor
Fischer Stephan
Kopetzki Erhard
Ries Stefan
Sankuratri Suryanarayana
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2008002092A1 publication Critical patent/CL2008002092A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Conjugado que contiene dos o más péptidos antifusogénicos y un anticuerpo anti-cd4; método de producción; composición farmacéutica que lo comprende; y su uso para tratar infecciones víricas.
CL2008002092A 2007-07-20 2008-07-17 Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. CL2008002092A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07014335 2007-07-20

Publications (1)

Publication Number Publication Date
CL2008002092A1 true CL2008002092A1 (es) 2009-05-29

Family

ID=38825000

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002092A CL2008002092A1 (es) 2007-07-20 2008-07-17 Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.

Country Status (14)

Country Link
US (1) US20090022720A1 (es)
EP (2) EP2526972A1 (es)
JP (1) JP2010534212A (es)
KR (1) KR20100049547A (es)
CN (2) CN103554271A (es)
AR (1) AR067584A1 (es)
AU (1) AU2008280443B2 (es)
BR (1) BRPI0814533A2 (es)
CA (1) CA2693663A1 (es)
CL (1) CL2008002092A1 (es)
IL (1) IL202565A0 (es)
PE (1) PE20090503A1 (es)
TW (1) TW200914467A (es)
WO (1) WO2009012944A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2695999T3 (es) 2007-10-12 2019-01-11 Hoffmann La Roche Expresión de proteínas a partir de múltiples ácidos nucleicos
EP2392351A4 (en) * 2009-01-28 2012-12-12 Univ Tokai Educational System HIV REPLICATION HEMMER AND ITS USE
JP5757639B2 (ja) * 2010-09-14 2015-07-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ セルピンフィンガー融合ポリペプチド
US8440797B2 (en) 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
AU2011339414A1 (en) * 2010-12-06 2013-07-04 Sumitomo Dainippon Pharma Co., Ltd. Human monoclonal antibody
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
CR20170482A (es) 2015-04-24 2018-03-07 Viiv Healthcare Uk No 5 Ltd Polipéptidos dirigidos a la fusión de vih
CN105039379A (zh) * 2015-08-31 2015-11-11 浙江大学 一种大肠杆菌无细胞体系生产HIV-1 gp41重组抗原的方法
US11787858B2 (en) 2016-12-22 2023-10-17 Icahn School Of Medicine At Mount Sinai Anti-LILRB3 antibodies and methods of use thereof
CN111278461A (zh) * 2017-08-16 2020-06-12 百时美施贵宝公司 可前药化抗体、其前药以及使用和制备方法
WO2020053239A1 (en) * 2018-09-11 2020-03-19 Nanotag Biotechnologies Gmbh Epitope tags recognized by specific binders
US11254736B2 (en) * 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
CN113461811A (zh) * 2021-06-30 2021-10-01 复旦大学 一种双特异性抗hiv-1抗体
WO2025006684A1 (en) * 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8603765D0 (en) * 1986-02-15 1986-03-19 Beecham Wuelfung Gmbh & Co Kg Compounds
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
JPH0468776A (ja) * 1990-07-04 1992-03-04 Pioneer Electron Corp 情報記録及び静止画再生装置
AU662891B2 (en) 1990-11-27 1995-09-21 Biogen Idec Ma Inc. Anti CD-4 antibodies blocking HIV-induced syncytia
ATE327331T1 (de) 1991-07-25 2006-06-15 Biogen Idec Inc Rekombinante antikörper zur humanen therapie
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AU688733B2 (en) * 1992-07-20 1998-03-19 Duke University Compounds which inhibit HIV replication
AU6912294A (en) 1993-05-12 1994-12-12 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
EP1161955A3 (en) 1995-05-18 2001-12-19 Ortho Pharmaceutical Corporation Induction of immunological tolerance for graft transplantation by the use of humanized non-depleting anti-cd4 antibodies in combination with specific donor bone marrow cells
US6475491B1 (en) 1995-06-07 2002-11-05 Trimeris, Inc. Treatment of HIV and other viral infections using combinatorial therapy
US5646480A (en) * 1995-06-19 1997-07-08 Northrop Grumman Corporation Metal assist structure for an electroluminescent display
ES2270461T3 (es) 1996-06-03 2007-04-01 United Biomedical, Inc. Anticuerpos contra un complejo de cd4 y un dominio receptor de quemoquina, y sus usos contra las infecciones de vih.
US6020159A (en) 1996-09-24 2000-02-01 Smithkline Beecham Corporation 3-dehydroquinate synthase
WO1998033523A1 (en) 1997-01-31 1998-08-06 Biovation Limited Vaccination methods and molecules
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US20030103984A1 (en) * 1998-05-04 2003-06-05 Heinz Kohler Fusion proteins of biologically active peptides and antibodies
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
TR200101049T2 (tr) * 1998-10-13 2002-01-21 Fujisawa Pharmaceutical Co. Ltd. Siklik tetrapeptid bileşiği ve kullanımı
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US6138310A (en) * 1999-04-23 2000-10-31 Porper; Robert P. Electric toothbrush having opposed bristle heads
TWI230178B (en) * 1999-05-13 2005-04-01 Sumitomo Chemical Co Liquid crystal polyester resin composition and molded article thereof
BR0010757A (pt) 1999-05-17 2002-02-19 Conjuchem Inc Inibidores de peptìdeo de fusão de longa duração de infecção viral
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6430559B1 (en) * 1999-11-02 2002-08-06 Claritech Corporation Method and apparatus for profile score threshold setting and updating
AU2265701A (en) 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
JP5179689B2 (ja) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
JP5390055B2 (ja) * 2000-06-29 2014-01-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
CA2475382A1 (en) * 2002-02-07 2003-08-14 Delta Biotechnology Limited Albumin-fused anti-angiogenesis peptides
EP1543166A4 (en) * 2002-09-27 2009-10-28 Genentech Inc SYNERGETIC COMPOSITIONS FOR PREVENTING AND TREATING THE ACQUIRED IMMUNE WEAKNESS SYNDROME
US20040076637A1 (en) 2002-09-27 2004-04-22 Delmedico Mary Kay HIV-derived HR1 peptides modified to form stable trimers, and their use in therapy to inhibit transmission of human immunodeficiency virus
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
NZ543122A (en) 2003-03-24 2008-07-31 Sequoia Pharmaceuticals Inc An HIV fusion inhibitor peptide covalently linked to a blood protein
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
WO2004108885A2 (en) 2003-05-06 2004-12-16 Syntonix Pharmaceuticals, Inc. Fc chimeric proteins with anti-hiv drugs
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2004103312A2 (en) 2003-05-19 2004-12-02 Progenics Pharmaceuticals, Inc. Peptides useful as hiv fusion inhibitors
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
JP2007517522A (ja) 2004-01-07 2007-07-05 トリメリス，インコーポレーテッド ＨＩＶｇｐ４１ＨＲ２由来の合成ペプチド、およびヒト免疫不全ウイルスの伝播を阻止する治療におけるその使用
JP2009514508A (ja) * 2005-10-24 2009-04-09 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
KR101105610B1 (ko) * 2006-08-17 2012-01-18 에프. 호프만-라 로슈 아게 Ｃｃｒ５ 에 대한 항체 및 항푸소제닉 펩타이드의 컨쥬게이트

Also Published As

Publication number Publication date
IL202565A0 (en) 2010-06-30
EP2178566A1 (en) 2010-04-28
WO2009012944A1 (en) 2009-01-29
AU2008280443A1 (en) 2009-01-29
KR20100049547A (ko) 2010-05-12
CN102099057B (zh) 2013-11-13
PE20090503A1 (es) 2009-04-29
CA2693663A1 (en) 2009-01-29
TW200914467A (en) 2009-04-01
US20090022720A1 (en) 2009-01-22
JP2010534212A (ja) 2010-11-04
CN103554271A (zh) 2014-02-05
EP2526972A1 (en) 2012-11-28
CN102099057A (zh) 2011-06-15
BRPI0814533A2 (pt) 2015-01-27
AU2008280443B2 (en) 2013-08-01
AR067584A1 (es) 2009-10-14

Similar Documents

Publication Publication Date Title
BR112020002012A8 (pt) Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
CL2011000086A1 (es) Anticuerpo aislado o proteina funcional contra el polipeptido baffr que inhibe la proliferacion de celulas b; secuencia nucleotidicas de dicho anticuerpo; vector y celula huesped que comprende dicha secuencia; y su uso para tratar enfermedades autoinmunes o neoplasias de celulas b.
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
BR112018075649A2 (pt) anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
CO6630164A2 (es) Proteinas que se unen al tnf-a
EA201890315A1 (ru) Молекулы антител, связывающие cd22
CR20110091A (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
MX2017008186A (es) Anticuerpos humanos para la hemaglutinina de influenza.
CU20170169A7 (es) Anticuerpos de factor xi
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
AU2012249274A8 (en) Neutralizing antibodies to Nipah and Hendra virus
CL2007003303A1 (es) Molecula de enlace para la proteina lingo-1; polinucleotido que la codifica; vector y celula que lo comprenden; composicion farmaceutica que comprende la molecula de enlace; y su uso para el tratamiento de lesiones del sistema nervioso central.
ECSP11011297A (es) Proteinas ligadoras il-17
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
CL2011002524A1 (es) Compuestos derivados de 1,3-diazol-fenil-(etinil, etenil o ciclopropil)-fenil-1,3-diazol sustituidos, inhibidores ns5a; composicion farmaceutica que los comprende y su uso en tratamiento de la hepatitis c.
UA113712C2 (xx) Антитіло до fap і способи його застосування
CL2008001467A1 (es) Peptidos cilindricos antagonistas de cxcr4 ciclado por lactamas: composicion farmaceutica que los comprenden; y su uso para tratar artitis reumatica, fibrosis pulmonar, infeccion por vih o cancer.
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
MX2016002166A (es) Anticuerpos.